Clinical Trials Logo

Clinical Trial Summary

The main objective of this study is to characterize the biological responses elicited by endotoxin inhalation applied to healthy subjects, and to assess the effect of standard anti-inflammatory agents (i.e. adalimumab and methylprednisolone) on these biological responses.


Clinical Trial Description

This open-label, single-center, parallel-group clinical trial is designed to evaluate Humira® or methylprednisolone versus no treatment in healthy subjects applied inhaled endotoxin challenges.

A total of 30 healthy adult subjects who meet all inclusion and exclusion criteria will be randomised in a 1:1:1 ratio to one of the following cohorts:

- Cohort 1 subjects receive no study drug during the study.

- Cohort 2 subjects receive an oral 7-day course of the corticosteroid (methylprednisolone) during the study, starting on study Day 1. The daily dose is 20 mg.

- Cohort 3 subjects receive a single subcutaneous injection of the anti-tumor necrosis factor (TNF) (adalimumab) on study Day 1, administered as a 40 mg dose.

The study will include a Screening period of up to 21 days, during which subject eligibility will be assessed and Screening responses to endotoxin exposure challenge will be collected. Eligible subjects will initially undergo an 8-day treatment period, during which they will receive treatment based on their assigned cohort (or will receive no treatment if assigned to Cohort 1) and will be applied with the endotoxin challenges. After the treatment period, subjects will be followed up until study Day 42.

Efficacy evaluations will include specific responses to endotoxin challenge, and effects of methylprednisolone and adalimumab on these responses. Safety will be monitored throughout the study. ;


Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


NCT number NCT02252809
Study type Interventional
Source Brugmann University Hospital
Contact
Status Completed
Phase Phase 0
Start date November 2008
Completion date July 2009

See also
  Status Clinical Trial Phase
Completed NCT06123910 - Bovine Colostrum Supplementation in Athletes N/A
Completed NCT03639376 - Passive Smoking and LL-37 in Children
Recruiting NCT04816760 - Immune Cells Phenotypes During COVID-19
Completed NCT01386489 - Immune Responses to Two Experimental HIV Vaccines in Healthy Adults Phase 1
Recruiting NCT03379207 - Innate Immune Response During Community Acquired Pneumonia
Not yet recruiting NCT04256356 - Immunity Modification of Full Term Infants According to the Type of Feeding and Mode of Delivery N/A
Completed NCT02953327 - Testing if BCG (Bacille Calmette-Guérin) Vaccination Can Induce Innate Immune Training in Adult People Above 50 Years of Age in Guinea-Bissau Phase 4
Completed NCT03637894 - Immunity Modification of Full Term Infants According to the Type of Feeding and Mode of Delivery N/A
Completed NCT03886350 - Implication of UNconventionaL T Lymphocytes in Cystic Fibrosis (UNLOCk)